P

    Pyxis Oncology Inc (PYXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.24
    +0.01 (+0.31%)

    Market Cap: $270.24M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(10/20)
    Avg Surprise
    -33.12%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.28
    Range$-0.36 - $-0.22
    9 analysts
    EPS Revisions
    1
    0
    7d
    1
    2
    30d
    EPS Estimate Drift
    90d ago$-0.28-0.4%
    60d ago$-0.28-1.3%
    30d ago$-0.28+1.0%
    7d ago$-0.28+0.4%
    Current$-0.28
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.24
    Range$-0.51 - $-0.01
    9 analysts
    Revenue Consensus
    $-2780
    Range$-22220 - $152780
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.24---
    Sep 26EST
    		-$-0.28---
    Jun 26
    Reported Aug 13
    		$-0.40$-0.34-17.65%Miss-33.3%
    Mar 26
    Reported May 14
    		$-0.37$-0.35-5.71%Miss-5.7%
    Dec 25
    Reported Mar 23
    		$-0.29$-0.33+11.83%Beat+78.0%
    Sep 25
    Reported Nov 3
    		$-0.35$-0.34-2.94%Miss+0.0%
    Jun 25
    Reported Aug 14
    		$-0.30$-0.35+14.29%Beat-3.4%
    Mar 25
    Reported May 15
    		$-0.35$-0.29-20.69%Miss-483.3%
    Dec 24
    Reported Mar 18
    		$-1.32$-0.32-312.50%Miss-300.0%
    Sep 24
    Reported Nov 12
    		$-0.35$-0.31-12.90%Miss+37.5%
    Jun 24
    Reported Aug 14
    		$-0.29$-0.33+12.12%Beat+29.3%
    Mar 24
    Reported May 14
    		$-0.06N/A+75.00%Beat+89.1%
    Dec 23
    Reported Mar 21
    		$-0.33$-0.47+29.79%Beat+68.3%
    Sep 23
    Reported Nov 7
    		$-0.56$-0.51-9.80%Miss+34.1%
    Jun 23
    Reported Aug 11
    		$-0.41$-0.66+37.88%Beat+48.1%
    Mar 23
    Reported May 11
    		$-0.55$-0.90+38.89%Beat+43.3%
    Dec 22
    Reported Mar 22
    		$-1.04$-1.01-2.97%Miss+47.5%
    Sep 22
    Reported Nov 1
    		$-0.85$-0.89+4.49%Beat-88.9%
    Jun 22
    Reported Aug 15
    		$-0.79$-0.92+14.13%Beat+22.5%
    Mar 22
    Reported May 13
    		$-0.97$-0.50-94.00%Miss+93.9%
    Dec 21
    Reported Mar 29
    		$-1.98$-0.37-435.14%Miss+87.6%
    Sep 21
    Reported Oct 8
    		$-0.45$-0.52+13.46%Beat+83.6%
    Jun 21
    Reported Sep 1
    		$-1.02$0.00N/AMiss+62.7%
    Mar 21
    Reported Jun 30
    		$-15.93$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-15.93$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-2.74$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-2.74$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.30EV/EBITDA1.09x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-813.00%
    ROE-179.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.34xQuick Ratio1.34x
    Trading Statistics
    Beta1.32Avg Volume1.37M
    52-Week High$5.5552-Week Low$1.03

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.17
    SMA 20$3.22
    SMA 50$2.84
    SMA 200$2.29
    EMA 10$3.19
    EMA 20$3.12
    EMA 50$2.84
    EMA 200$2.29

    MACD

    Line: 0.12Signal: 0.13Hist: -0.02

    ADX

    ADX: 17.6+DI: 22.8-DI: 24.6

    Aroon & PSAR

    Aroon Up44.0
    Aroon Down44.0
    PSAR$3.51

    Bollinger Bands

    Upper Band$3.77
    Lower Band$2.67
    %B Position3410%(Upper)
    Band Width0.52

    RSI (14-Day)

    Neutral
    54.5

    Momentum Oscillators

    Stoch %K65.9
    Stoch %D65.4
    Williams %R-33.3
    ROC (10d)7.3%
    Momentum0.22
    CCI (20d)-3.8
    MFI (14d)47.4

    Volatility Measures

    ATR (14d)$0.33(10.1%)
    StdDev (20d)0.27
    Hist Vol145.9%(High)

    Volume Flow

    VWAP$3.19
    OBV18.4M
    AD Line5.6M
    CMF (20d)0.076

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.3x(Low)
    VWMA (20d)$3.09

    Pivot Points

    R3$3.52
    R2$3.45
    R1$3.34
    Pivot Point$3.27
    S1$3.16
    S2$3.09
    S3$2.98

    Advanced Oscillators

    TSI9.12
    Ultimate Osc62.1
    KST136.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$389,000$631,000$9.15M$684,000$2.82M$515,000$-2,212,000$705,000$708,000$16.95M$576,000$598,000
    Cost of Revenue$0$0$2.39M$0$0$0$1.70M$0$0$475,000$763,000$0
    Gross Profit$389,000$631,000$6.77M$684,000$2.82M$515,000$-2,212,000$705,000$708,000$16.47M$576,000$598,000
    Operating Expenses$25.99M$24.36M$26.95M$23.46M$22.57M$22.91M$40.07M$23.75M$20.03M$21.28M$17.77M$25.35M
    R&D$16.06M$19.98M$21.71M$17.81M$17.13M$17.04M$14.02M$17.74M$13.95M$13.03M$11.61M$14.69M
    SG&A$9.93M$4.38M$5.23M$5.65M$5.44M$5.87M$5.08M$6.01M$6.08M$8.25M$6.16M$10.67M
    Operating Income$-25,990,000$-24,360,000$-18,295,000$-23,461,000$-19,750,000$-22,914,000$-40,069,000$-23,754,000$-20,032,000$-5,605,000$-17,767,000$-25,354,000
    Interest Income$255,000$457,000$600,000$774,000$995,000$1.24M$1.62M$1.85M$2.02M$1.55M$1.59M$1.71M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-25,346,000$-23,272,000$-17,003,000$-22,003,000$-18,071,000$-21,158,000$-37,735,000$-21,203,000$-17,301,000$-3,256,000$-15,559,000$-23,049,000
    Income Tax Expense$0$0$0$0$283,000$0$0$0$0$0$0$0
    Net Income$-25,346,000$-23,272,000$-18,106,000$-22,003,000$-18,354,000$-21,158,000$-35,571,000$-21,203,000$-17,301,000$-3,256,000$-15,597,000$-23,049,000
    EBITDA$-25,883,000$-24,140,000$-15,773,000$-23,466,000$-19,427,000$-23,519,000$-41,052,000$-24,675,000$-21,083,000$-5,777,000$-18,518,000$-25,354,000
    EBIT$-25,990,000$-24,360,000$-18,295,000$-23,461,000$-19,066,000$-22,914,000$-40,069,000$-23,754,000$-20,032,000$-5,605,000$-17,767,000$-25,354,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PYXS

    News

    Pyxis Oncology (PYXS) awards director options at $3.12

    Pyxis Oncology (PYXS) announced that director Jakob Dupont was awarded 46,000 stock options on August 20, 2026, with an exercise price of $3.12 per share and an expiration date of August 20, 2036. The options will vest in equal monthly installments through October 31, 2026, contingent on his continued service. Following this grant, Dupont holds 46,000 options directly.

    Stock Titan•8/21/26•
    Neutral

    Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

    HC Wainwright has raised its Q3 2026 EPS estimate for Pyxis Oncology to a loss of $0.26 per share from $0.27, while maintaining a Buy rating and a $7 price target. The firm also improved longer-term forecasts, projecting reduced losses for FY2026 and FY2027 and anticipating positive EPS of $0.23 in FY2029. Despite Pyxis Oncology missing recent quarterly earnings expectations and remaining unprofitable, the stock saw a 12.7% increase, and analysts overall rate it a “Moderate Buy.”

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright

    HC Wainwright has lowered its FY2030 EPS forecast for Pyxis Oncology (NASDAQ:PYXS) to $0.76 from $0.77, while maintaining a "Buy" rating and a $7.00 price target. The company recently reported a quarterly loss of $0.40 per share, missing consensus estimates. Despite various analyst rating adjustments, the consensus rating for Pyxis Oncology remains "Moderate Buy" with a target price of $7.50.

    MarketBeat•8/19/26•
    Neutral

    H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7

    H.C. Wainwright has reiterated its Buy rating for Pyxis Oncology (PYXS.US) and maintained a target price of $7. This indicates a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•8/19/26•
    Bullish

    Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)

    The article highlights bullish sentiments from analysts in the Healthcare sector, focusing on BridgeBio Pharma (BBIO) and Pyxis Oncology (PYXS). RBC Capital maintained a Buy rating for BridgeBio Pharma with a $100 price target, while RBC Capital also maintained a Buy rating for Pyxis Oncology with a $5.00 price target. Both companies received strong buy consensus ratings from the street, indicating significant potential upside.

    The Globe and Mail•8/16/26•
    Bullish

    Frequently Asked Questions About PYXS

    Does PYXS pay dividends?
    Pyxis Oncology Inc (PYXS) does not currently pay a regular dividend.
    What is PYXS's market cap?
    Pyxis Oncology Inc (PYXS) has a market capitalization of $270.24M with a current stock price of $3.24.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In